The medtech sector, like the wider pharma market, has been having a tough time. There are, however, glimmers of light and some interesting developments – including ongoing digitisation and the emergence of new types of liquid biopsies.
Medtech: Going steady explores these issues in more detail and reveals insights from the latest consensus forecasts out to 2028.
Look out for the Evaluate Vantage Medtech World Preview, coming soon.
.
HIGHLIGHTS INCLUDE:
The top 10 medtech players in 2028 – including who’s growing, but still falling down the leader board.
The top 10 device areas in 2028 – spoiler alert: in vitro diagnostics might be taking a post-Covid hit, but it’s still the biggest area, followed by cardiology.
R&D spend out to 2028 – and who’s likely to be getting the best bang for their buck.
